Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study.
Saved in:
| Title: | Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study. |
|---|---|
| Authors: | Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Jhaveri K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Helsten T; Moores Cancer Center, University of California San Diego, San Diego, CA, United States., Puhalla SL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States., Conlin A; Providence Cancer Center, Portland, OR, United States., Dees EC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Beeram M; South Texas Accelerated Research Therapeutics, San Antonio, TX, United States., Chapman SC; Eli Lilly and Company, Indianapolis, IN, United States., Lithio A; Eli Lilly and Company, Indianapolis, IN, United States., Litchfield LM; Eli Lilly and Company, Indianapolis, IN, United States., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, MN, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Mar 12; Vol. 15, pp. 1555921. Date of Electronic Publication: 2025 Mar 12 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
